Altamira Therapeutics Ltd.
CYTO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $4 | $22 |
| - Cash | $1 | $1 | $0 | $1 |
| + Debt | $0 | $0 | $6 | $1 |
| Enterprise Value | -$1 | $1 | $10 | $22 |
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | -100% | 378.4% | – |
| Gross Profit | – | $0 | -$1 | -$2 |
| % Margin | – | – | -372.4% | -3,407.3% |
| EBITDA | – | -$1 | -$18 | -$7 |
| % Margin | – | – | -5,770.6% | -10,512.8% |
| Net Income | – | -$7 | -$27 | -$17 |
| % Margin | – | – | -8,680.2% | -26,703.1% |
| EPS Diluted | – | -14.8 | -582.58 | -515.11 |
| % Growth | – | 97.5% | -13.1% | – |
| Operating Cash Flow | -$6 | -$12 | -$9 | -$14 |
| Capital Expenditures | -$0 | $0 | -$2 | -$3 |
| Free Cash Flow | -$6 | -$12 | -$11 | -$17 |